Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophia Huesmann

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Oncology Research and Treatment|February 25, 2025
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?Kerstin Pfister, Henning Schäffler, Sophia Huesmann, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.
Geburtshilfe Und Frauenheilkunde|September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast CentersHenning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Oncology Research and Treatment|February 25, 2025
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?Kerstin Pfister, Henning Schäffler, Sophia Huesmann, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.
Geburtshilfe Und Frauenheilkunde|September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast CentersHenning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
Pageof 1